Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Apricus Biosc Inc (APRI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Apricus Biosciences Provides Corporate Update and First Quarter 2018 Financial Results

Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company seeking to advance innovative medicines in urology and rheumatology, today reported financial results for the first quarter of 2018...

APRI : 0.29 (unch)
Dthera Sciences Appoints Steve R. Martin to Board of Directors

SAN DIEGO, CA / ACCESSWIRE / April 16, 2018 / Dthera™ Sciences (OTCQB: DTHR), a digital therapeutics company focused on developing the innovative quality of life therapies for the elderly and those suffering...

APRI : 0.29 (unch)
DTHR : 0.5000 (-5.66%)
DTHRD : N/A (unch)
Apricus Biosciences Announces Outcome of Vitaros(TM) End-of-Review Meeting with FDA

FDA Confirms Vitaros Regulatory Pathway

APRI : 0.29 (unch)
Apricus Biosciences Announces Closing of $3.55 Million Public Offering

Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the closing of its previously announced public offering...

APRI : 0.29 (unch)
Apricus Biosciences Announces Pricing of $3.55 Million Public Offering

SAN DIEGO, March 28, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has...

APRI : 0.29 (unch)
Apricus Biosciences Announces Proposed Public Offering

Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has commenced a public offering of shares of common...

APRI : 0.29 (unch)
Apricus Biosciences Announces Scheduling of Vitaros(TM) End-of-Review Meeting with FDA

Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that its end-of-review meeting with the U.S. Food and Drug...

APRI : 0.29 (unch)
Blog Exposure - Cipher to Acquire Cardiome's Canadian Business Portfolio for $25.5 Million in Cash

Stock Monitor: Apricus Biosciences Post Earnings Reporting

APRI : 0.29 (unch)
CRME : 2.33 (-2.10%)
Quotidian Technical Highlights on Selected Drug Makers Stocks -- Amarin, Apricus Biosciences, United Therapeutics, and Novo Nordisk

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on AMRN, APRI, UTHR, and NVO which can be accessed for free by signing up to www.wallstequities.com/registration....

AMRN : 3.04 (+1.33%)
NVO : 48.10 (-0.35%)
APRI : 0.29 (unch)
UTHR : 104.73 (-0.79%)
Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial Results

Company Expects to Submit Vitaros End of Review Meeting Request This Month

APRI : 0.29 (unch)
Apricus Biosciences, Inc. : Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial Results

Company Expects to Submit Vitaros End of Review Meeting Request This Month

APRI : 0.29 (unch)
Apricus Biosciences (APRI) Soars: Stock Adds 8.6% in Session

Shares of Apricus Biosciences (APRI) rose about 9% yesterday.

SMMT : 13.22 (-2.00%)
APRI : 0.29 (unch)
Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2017 Financial Results Conference Call

SAN DIEGO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's...

APRI : 0.29 (unch)
Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros(TM)

Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the U.S. Food and Drug Administration ("FDA") has issued...

APRI : 0.29 (unch)
SeeThruEquity Issues Update Note on Apricus Biosciences, Inc. (Nasdaq CM: MTBC) with Target Price of $4.30

NEW YORK, NY / ACCESSWIRE / November 7, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has...

APRI : 0.29 (unch)
MTBC : 3.38 (-1.46%)
Apricus Biosciences Provides Corporate Update and Third Quarter 2017 Financial Results

Vitaros U.S. NDA Resubmission Review Remains on Track

APRI : 0.29 (unch)
Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call

Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Apricus' third quarter 2017 financial results will...

APRI : 0.29 (unch)
Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call

SAN DIEGO, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Apricus'...

APRI : 0.29 (unch)
Apricus Biosciences to Present at the 2017 BIO Investor Forum

SAN DIEGO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard...

APRI : 0.29 (unch)
Apricus Biosciences to Present at the 2017 BIO Investor Forum

Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard Pascoe, Chief Executive Officer, will present...

APRI : 0.29 (unch)

Van Meerten Stock Picks

5 Great Growth Stocks
This morning I wanted to find 5 stocks that were predicted to have double digit growth in both Revenue and Earnings over the next 5 years that were also having great current performance.
LULU +1.14 , ABMD -1.06 , AAXN +2.28 , NSP +0.90 , ERI +1.00
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Brugler Ag Report

Today's Commentary

Corn futures were weak into the close on Thursday, down 3 to 4 1/4 cents lower in the front months. Traders were taking money off the table ahead of the extended weekend. The USDA reported a private cancelation of 132,000 of grain sorghum to unknown ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar